RxDoctor Payments Data

Mark Seraly, MD

Dermatology · Mc Murray, PANPI 1912907452

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $408,529 of the $545,286 with a category attached, or 74.9%. 44 manufacturers reported payments, led by Amgen at 39.5% of the total. Reporting peaked in 2019 at $170,188 and has fallen 69.0% since, to $52,773 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$545,286in general payments, 2019–2025

Across 1,894 payments — averaging $287.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$216K
  • AbbVie$140K
  • Bristol Myers Squibb$70K
  • Arcutis Biotherapeutics, Inc.$54K
  • E.r. Squibb & Sons, L.L.C.$35K
  • Kowa Pharmaceuticals America, Inc.$9K
  • plus $21K from 38 others

What the payments were for

  • Consulting fees$62,79312%
  • Speaking & faculty fees$408,52975%
  • Travel & lodging$40,1877%
  • Food & beverage$33,3026%
  • Education$4750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545,286 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$593,445
Medicare patients
946
Services billed
34,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept25$182,035
OtezlaApremilast28$133,950
Taltz AutoinjectorIxekizumab12$81,657
Dupixent PenDupilumab21$78,799
CibinqoAbrocitinib11$59,009
ZoryveRoflumilast17$13,900
Clobetasol Propionate188$10,885
Acitretin23$9,225
Fluorouracil76$5,269
Ciclopirox65$4,030
Imiquimod98$2,510
Doxycycline Hyclate130$2,336
Triamcinolone Acetonide192$2,305
Clindamycin Phosphate60$2,266
Desonide51$2,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$215,641$133,95028 claims
PfizerCibinqo$1,273$59,00911 claims
Arcutis Biotherapeutics, Inc.Zoryve$53,981$13,90017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →